Search PubMed⌕ Search

Biomedical subjects

J C Sisson

Publications and source records attributed to J C Sisson.

158 records · Page 9Linked to original sources
PubMedDate not supplied

Locating pheochromocytomas by scintigraphy using 131I-metaiodobenzylguanidine.

Scintigraphy with 131I-MIBG has located most pheochromocytomas. The detected tumors have been intra-adrenal, extra-adrenal, malignant, and familial in type. The method is safe, but requires images taken over three days to attain optimal results. Because of its ability to screen all sites where primary pheochromocytomas may reside, scintigraphy should be employed as the initial procedure in the search for these tumors. It may be the only technique that will locate extra-adrenal pheochromocytomas. The rate of false-negative results is about 10 percent; therefore, other techniques such as computed tomography will be necessary to help find the few elusive pheochromocytomas.

3-Iodobenzylguanidine↗
PubMedDate not supplied

Radioiodine therapy of thyrotoxicosis.

Radioactive iodine treatment of thyrotoxicosis in considered one of, if not the most, successful therapy in Nuclear Medicine. A sixty year experience in virtually hundreds of thousands of patients supports the safety, efficacy and cost effectiveness of radioiodine. However, despite all of the data amassed since its introduction almost all aspects of its use from the indications, selection of patients, goals of therapy and selection of doses in the treatment of hyperthyroidism remain controversial and continue to be a subject of lively debate.

Humans↗
PubMedDate not supplied

Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma.

Fourteen patients with advanced neuroblastoma, which was unresponsive to or had relapsed despite conventional therapy, were entered into a phase I/II trial of [131I]metaiodobenzylguanidine (131I-MIBG). Doses ranged from 1.85-8.14 GBq each (50-220 mCi), with cumulative doses of 1.85-24.20 GBq (50-654 mCi) in one to three doses. Side effects included mild nausea and vomiting and moderate myelosuppression which occurred in nine patients. Subjective responses occurred in five patients. Four patients had objective responses (one partial, two minor and one mixed). Two of these patients remain alive 80 and 60 months after beginning 131I-MIBG therapy. Comparison of the 131I-MIBG treated patients with 11 carefully matched control patients treated with an advanced current chemotherapy protocol (CCG 8605) was performed by means of Kaplan-Meier life table analysis. The 14% four-year survival with 131I-MIBG compared favorably with the 6% achieved by salvage chemotherapy. We thus believe 131I-MIBG may have a role in the management of neuroblastoma.

3-Iodobenzylguanidine↗
PubMedDate not supplied

Treatment of neuroblastoma with [125I]metaiodobenzylguanidine.

To find a treatment that may be effective against micrometastases of advanced, stage III or IV neuroblastoma, [125I]metaiodobenzylguanidine (125I-MIBG) was used in a phase I toxicity trial. In seven patients, thrombocytopenia was encountered with absorbed whole body doses of 85-135 rad from 125I-MIBG, but the dosimetry was imprecise in predicting bone marrow injury. Three patients survived for over one year, results that may indicate efficacy of 125I-MIBG therapy.

3-Iodobenzylguanidine↗
PubMedDate not supplied

Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience.

Twenty-eight patients with histologically proven metastatic or invasive, unresectable pheochromocytomas, which were shown to concentrate and retain tracer doses of [131I]metaiodobenzylguanidine (131I-MIBG), were treated with therapeutic quantities of this radiopharmaceutical. Between one and six doses ranging from 97 to 301 mCi (cumulative dose 111-916 mCi) were administered. Partial response in tumor size was achieved in 8/28 patients and partial biochemical responses in 12/28 patients. No pharmacological toxicity was observed. Mild radiation sickness (nausea, vomiting, anorexia) occurred in 21/28. Minor degrees of leukopenia and thrombocytopenia were observed in 3/28. There were three cases of hypothyroidism but no significant hepatic, renal, adrenocortical or autonomic nervous dysfunction. We conclude that therapeutic 131I-MIBG can achieve significant therapeutic responses in some cases of malignant pheochromocytoma without pharmacological toxicity and only mild radiotoxicity.

3-Iodobenzylguanidine↗
PubMedDate not supplied

MR imaging of the thyroid: comparison with scintigraphy in the normal and diseased gland.

Spin-echo magnetic resonance (MR) imaging of the thyroid gland was performed in patients using a superconducting magnet operating at 0.35 T. There were 17 women and two men with an age range of 21-77 years. All of the patients with disease were also evaluated with scintigraphy and three of the four subjects with normal thyroid glands also had scintigraphy. Final diagnoses in the patients were normal gland in four, Graves disease in two, thyroid cyst in one, benign follicular adenoma in two, papillary cell carcinoma in one, Hürthle cell carcinoma in one, Hashimoto thyroiditis in one, and multinodular goiter in seven. The normal thyroid and surrounding anatomy were clearly demonstrated by intrinsic signal intensity differences of the tissues. The thyroid gland in Graves disease was enlarged and had homogeneously increased signal intensity at all pulse sequences compared with skeletal muscle and normal thyroid. The thyroid cyst and benign adenoma were well defined; however, the cyst displayed the greater signal intensity on more T2-weighted pulse sequences. The MR signal intensity features of multinodular goiter and Hashimoto thyroiditis appear similar to those of the normal gland. In cases of focal masses, MR could not reliably distinguish benign from malignant tumor. However, using intensity ratio data there was a statistically significant difference between solid and hemorrhagic cystic disease.

Adenoma↗